Watch CRL. Know when insiders buy.
One email the day a filing lands. Free.
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
339.66
−5.21 −1.51%
USD · close Oct 22
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
32
FLAG · insiders 30, shorts 33
Insiders, 90 days
−$11.1M
net selling · 1 buy, 4 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $16.2BP/E —DIV YIELD —FCF YIELD 2.29%REV TTM $4B −0.7%NET INCOME −$238.5MNET DEBT $1.4B52W 149.93 – 344.87NEXT EARNINGS Nov 4SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 27 | $1B | −2.7% | — | $119.9M | −$1.5M | −102.8% | -0.03 | $179.7M | $31.1M | $148.6M | Aug 5 |
| Q1 2026 · Mar 28 | $995.8M | +1.2% | — | $119.9M | −$14.8M | −158.3% | -0.30 | $41.1M | $55.9M | −$14.8M | May 7 |
| Q4 2025 · Dec 27derived | $994.2M | −0.8% | — | −$283.4M | −$276.6M | — | -5.56 | $147.5M | $89M | $58.6M | Feb 18 |
| Q3 2025 · Sep 27 | $1B | −0.5% | — | $133.8M | $54.4M | −21.9% | 1.10 | $213.8M | $35.6M | $178.2M | Nov 5 |
| Q2 2025 · Jun 28 | $1B | +0.6% | — | $100.1M | $52.3M | −44.4% | 1.06 | $204.6M | $35.3M | $169.3M | Aug 5 |
| Q1 2025 · Mar 29 | $984.2M | −2.7% | — | $74.7M | $25.5M | −65.1% | 0.50 | $171.7M | $59.3M | $112.4M | May 7 |
| Q4 2024 · Dec 28derived | $1B | −1.1% | — | −$167.7M | −$214.5M | −214.7% | -4.17 | $159.4M | $75.6M | $83.7M | Feb 18 |
| Q3 2024 · Sep 28 | $1B | −1.6% | 34.6% | $117.4M | $69.7M | −20.3% | 1.33 | $251.8M | $38.7M | $213.1M | Nov 5 |
| Q2 2024 · Jun 29 | $1B | — | 34.5% | $151.7M | $94.1M | — | 1.74 | $193.5M | $39.5M | $154M | Aug 6 |
| Q1 2024 · Mar 30 | $1B | — | 34.1% | $126M | $73M | — | 1.30 | $129.9M | $79.1M | $50.7M | May 7 |
| Q4 2023 · Dec 30derived | $1B | — | — | $132.9M | $187.1M | — | 3.64 | $220.9M | $78.3M | $142.6M | Feb 18 |
| Q3 2023 · Sep 30 | $1B | — | 35.2% | $151.5M | $87.4M | — | 1.69 | $205.4M | $65.9M | $139.5M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 27 | $4B | — | $25.2M | −$144.3M | -3.6% | -2.91 | $737.6M | $219.2M | $518.5M | $360.7M | — |
| FY2024 · to Dec 28 | $4B | — | $227.3M | $22.2M | 0.5% | 0.20 | $734.6M | $233M | $501.6M | $119.2M | — |
| FY2023 · to Dec 30 | $4.1B | — | $617.3M | $474.6M | 11.5% | 9.22 | $683.9M | $318.5M | $365.4M | $24.2M | — |
| FY2022 · to Dec 31 | $4B | — | $651M | $486.2M | 12.2% | 9.48 | $619.6M | $324.7M | $294.9M | $38.7M | — |
| FY2021 · to Dec 25 | $3.5B | — | $589.9M | $391M | 11.0% | 7.60 | $760.8M | $228.8M | $532M | $40.7M | — |
| FY2020 · to Dec 26 | $2.9B | — | $432.7M | $364.3M | 12.5% | 7.20 | $546.6M | $166.6M | $380M | $24M | — |
Every number comes from CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.